Format

Send to

Choose Destination
Isr Med Assoc J. 2013 Aug;15(8):439-42.

Aortic valve-sparing surgery in Marfan syndrome.

Author information

1
Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel. Eyal.Nachum@sheba.health.gov.il

Abstract

BACKGROUND:

Patients with Marfan syndrome are referred for cardiac surgery due to root aneurysm with or without aortic valve regurgitation. Because these patients are young and frequently present with normal-appearing aortic cusps, valve sparing is often recommended. However, due to the genetic nature of the disease, the durability of such surgery remains uncertain.

METHODS:

Between February 2004 and June 2012, 100 patients in our department suffering from aortic aneurysm with aortic valve regurgitation underwent elective aortic valve-sparing surgery. Of them, 30 had Marfan syndrome, were significantly younger (30 +/- 13 vs. 53 +/- 16 years), and had a higher percentage of root aneurysm, compared with ascending aorta aneurysm in their non-Marfan counterparts. We evaluated the safety, durability, clinical and echocardiographic mid-term results of these patients.

RESULTS:

While no early deaths were reported in either group, there were a few major early complications in both groups. At follow-up (reaching 8 years with a mean of 34 +/- 26 months) there were no late deaths, and few major late complications in the Marfan group. Altogether, 96% and 78% of the patients were in New York Heart Association functional class I-II in the Marfan and non-Marfan groups respectively. None of the Marfan patients needed reoperation on the aortic valve. Freedom from recurrent aortic valve regurgitation > 3+ was 94% in the Marfan patients.

CONCLUSIONS:

Aortic valve-sparing surgery in Marfan symdrome patients is safe and yields good mid-term clinical outcomes.

PMID:
24079066
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Israel Medical Association
Loading ...
Support Center